Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phe
- PDF / 206,817 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 21 Downloads / 170 Views
CORRECTION
Open Access
Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines Karolin Ebert1, Gwen Zwingenberger1, Elena Barbaria1, Simone Keller1, Corinna Heck1, Rouven Arnold1, Vanessa Hollerieth1, Julian Mattes2, Robert Geffers3, Elba Raimúndez4,5, Jan Hasenauer4,5,6 and Birgit Luber1* Correction to: BMC Cancer 20, 1039 (2020) https://doi.org/10.1186/s12885-020-07540-7 Following publication of the original article [1], the authors reported an error in the labeling of Table 5. The corrected Table 5 is given below.
The original article can be found online at https://doi.org/10.1186/s12885020-07540-7. * Correspondence: [email protected] 1 Fakultät für Medizin, Technische Universität München, Klinikum rechts der Isar, Institut für Allgemeine Pathologie und Pathologische Anatomie, 81675 München, Germany Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Ebert et al. BMC Cancer
(2020) 20:1127
Page 2 of 2
Table 5 Candidate genes involved in phenotypic response to afatinib treatment a) Genes potentially involved in reduction of motility after afatinib treatment SERPINE1 HBEGF
F3 ITGA2
CXCL8 HAS2
PLPP3 SPRY2
F2RL1
PTGS2
CYR61
CXCL1
SEMA6D
ETS1
b) Genes potentially involved in induction of apoptosis after afatinib treatment BAX
BBC3
BCLAF1
CAV1
E2F1
FADD
FAF1
FAS
GSN
HYAL2
IL19
IL20RA
INHBB
LCK
LGALS9
NACC2
NF1
NFATC4
NKX3–1
PAK2
PARK7
PDCD5
PDIA3
PEA15
PPIF
PPP2R1B
PPP3CC
PRKRA
SFN
SFPQ
SKIL
SLC9A3R1
SMAD3
STK4
TGFBR1
TP73
TPD52L1
YWHAB
YWHAE
YWHAG
YWHAH
YWHAQ
YWHAZ
ZNF205
Genes that were regulated in MKN1 cells after 4 h afatinib and trastuzumab + afatinib treatment and were assigned to the biological function “positive regulation of cell motility” were selected (a). Genes that were regulated in NCI-N87 but not in MKN1 and MKN7 cells after 24 h afatinib and trastuzu
Data Loading...
